MK-1167 Phase 2 Alzheimer's Disease Trial

Overview

MK-1167 is an investigational drug developed by Merck Sharp & Dohme (MSD) in collaboration with the University of Kansas Alzheimer's Disease Research Center. The trial is a Phase 2 study evaluating MK-1167 as an adjunctive therapy for patients with mild to moderate Alzheimer's disease dementia. This trial represents Merck's continued investment in novel therapeutic approaches for Alzheimer's disease beyond the established amyloid-targeting and neurotransmitter-based strategies["@nct06721156"][@merckscience][@kumed].

Overview

MK-1167 is an investigational drug developed by Merck Sharp & Dohme (MSD) in collaboration with the University of Kansas Alzheimer's Disease Research Center. The trial is a Phase 2 study evaluating MK-1167 as an adjunctive therapy for patients with mild to moderate Alzheimer's disease dementia. This trial represents Merck's continued investment in novel therapeutic approaches for Alzheimer's disease beyond the established amyloid-targeting and neurotransmitter-based strategies["@nct06721156"][@merckscience][@kumed].

Alzheimer's disease is the most common cause of dementia worldwide, affecting approximately 6.5 million Americans alone. The disease is characterized by progressive cognitive decline, with amyloid-beta plaque accumulation and tau neurofibrillary tangles serving as hallmark pathological features. Despite significant research investment, only limited disease-modifying therapies have received approval, highlighting the urgent need for novel therapeutic approaches that target different aspects of disease pathogenesis.

Trial Details

| Attribute | Value |
|-----------|-------|
| NCT Number | NCT06721156 |
| Phase | Phase 2 |
| Sponsor | Merck Sharp & Dohme (MSD) |
| Collaborator | University of Kansas Alzheimer's Disease Research Center |
| Status | Recruiting |
| Participants | 350 |
| Study Start Date | Expected 2025 |
| Estimated Completion | 2027 |
| Age Range | 50-85 years |
| Diagnosis | Mild to Moderate Alzheimer's Disease |
| Intervention | MK-1167 (dose to be determined) |
| Control | Placebo |
| Randomization | 1:1 |
| Duration | 52 weeks (1 year) |

Trial Population Characteristics

The trial targets patients with mild to moderate Alzheimer's disease dementia, representing a critical window for therapeutic intervention. Patients in this disease stage typically exhibit measurable cognitive impairment but retain significant functional capacity, making them ideal candidates for disease-modifying therapies that may slow progression.

Inclusion Criteria:

• Diagnosis of probable Alzheimer's disease per NIA-AA criteria[@niaaa]
• MMSE score between 12-26 (mild to moderate dementia)
• Stable on acetylcholinesterase inhibitor or memantine therapy (if using) for at least 12 weeks
• Age 50-85 years
• Able to provide informed consent or have capable legal representative
• Confirmed presence of amyloid pathology via PET scan or CSF biomarkers

• Significant neurological disease other than AD
• Psychiatric disorder that could affect participation (e.g., major depression, schizophrenia)
• Significant medical comorbidities that would preclude study participation
• Use of investigational therapies within 30 days
• History of substance abuse within past year

Study Design

The trial employs a randomized, double-blind, placebo-controlled design, representing the gold standard for clinical efficacy assessment. Participants will be randomized to receive either MK-1167 at varying doses or placebo alongside standard of care therapy for Alzheimer's disease[@nct06721156].

Randomization and Blinding

The 1:1 randomization ensures equal distribution of patient characteristics between treatment and control arms. Double-blind design prevents bias from both investigators and participants knowing treatment assignment, ensuring objective assessment of outcomes. An independent data monitoring committee will conduct periodic safety reviews.

Treatment Arms

| Arm | Description |
|-----|-------------|
| Arm 1 | MK-1167 low dose + standard of care |
| Arm 2 | MK-1167 high dose + standard of care |
| Arm 3 | Placebo + standard of care |

Standard of care includes approved Alzheimer's medications such as donepezil, rivastigmine, galantamine, or memantine, either as monotherapy or combination therapy.

Mechanism of Action

The specific mechanism of MK-1167 has not been publicly disclosed. Merck has not revealed the molecular target or pathway being modulated. However, the development suggests a novel approach to Alzheimer's disease treatment beyond the established amyloid, tau, and neurotransmitter-based strategies.

Potential Mechanisms Under Investigation

Based on Merck's neuroscience pipeline and typical Phase 2 trial designs, several possibilities exist for MK-1167's mechanism:

Neuroinflammation Modulation:
The role of neuroinflammation in Alzheimer's disease pathogenesis has become increasingly recognized. Microglial activation, cytokine release, and inflammatory cascades contribute to neuronal damage. Novel anti-inflammatory approaches targeting specific inflammatory pathways may provide benefit beyond current therapies.

Synaptic Function Enhancement:
Synaptic loss correlates strongly with cognitive decline in Alzheimer's disease. Therapies that preserve or enhance synaptic function could potentially slow cognitive deterioration independent of amyloid or tau pathology.

Metabolic Support:
Brain energy metabolism is impaired in Alzheimer's disease. Interventions supporting neuronal metabolism, mitochondrial function, or glucose utilization may have therapeutic potential.

Proteostasis Restoration:
Dysregulated protein homeostasis contributes to amyloid and tau aggregation. Mechanisms promoting protein clearance or preventing aggregation represent active research areas.

Clinical Endpoints

Primary Endpoints

Cognitive Function:

• Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-13)
• Change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)
• MMSE score changes

• Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
• Functional Activities Questionnaire (FAQ)

Secondary Endpoints

Biomarker Outcomes:

• CSF amyloid-beta and tau levels
• Amyloid PET standardized uptake value ratio (SUVR)
• Tau PET imaging

• Adverse event frequency and severity
• Discontinuation rates
• Laboratory parameter changes
• Electrocardiogram changes

• Neuroimaging volumetry
• Fluid biomarker panels
• Pharmacokinetic profiling

Clinical Rationale

The trial is based on emerging research suggesting novel therapeutic targets in Alzheimer's disease pathogenesis. The collaboration with the University of Kansas ADRC indicates a focus on translating basic science findings into clinical applications[@kumed].

Unmet Need in Alzheimer's Disease

Despite advances in understanding Alzheimer's disease biology, significant gaps remain in therapeutic options:

Merck's Neuroscience Portfolio

Merck has maintained a significant neuroscience research program, with previous contributions to Alzheimer's disease therapeutics. Their pipeline includes multiple candidates targeting different aspects of disease pathogenesis[@merckscience].

Trial Sites

The trial is being conducted at multiple sites across the United States. Specific site locations will be listed on ClinicalTrials.gov when fully operational.

Participating Institutions

• University of Kansas Alzheimer's Disease Research Center (lead site)
• Major academic medical centers with memory disorders programs
• Specialized clinical research organizations

Regulatory Context

This trial operates under FDA oversight through the Investigational New Drug (IND) application process. The trial design aligns with FDA guidance for Alzheimer's disease drug development, incorporating:

• amyloid confirmation requirement
• validated cognitive endpoints
• biomarker substudies
• long-term follow-up considerations

Scientific Significance

The MK-1167 trial represents several important aspects of contemporary Alzheimer's disease research:

Novel Mechanism Exploration

By pursuing a mechanism distinct from amyloid-targeting antibodies (lecanemab, donanemab) or tau-targeting therapies, MK-1167 contributes to understanding whether alternative pathways can provide clinical benefit.

Adjunctive Therapy Paradigm

Evaluating MK-1167 as add-on to standard care reflects real-world treatment approaches where patients typically receive combination therapy.

Precision Medicine Approach

The use of biomarker confirmation (amyloid positivity) ensures enrolled patients have confirmed Alzheimer's pathology, potentially improving signal detection.

Risk and Considerations

Potential Benefits

• Novel mechanism with potential for disease modification
• Adjunctive design may provide additive benefit to standard care
• Participation contributes to Alzheimer's disease research

Potential Risks

• Unknown efficacy (Phase 2)
• Potential for adverse effects
• Time commitment (52 weeks)
• Site visits and assessments

Mitigation

• Close safety monitoring
• Independent data monitoring committee
• Standard of care maintained throughout

Related Clinical Trials

This trial joins numerous ongoing Phase 2 Alzheimer's disease studies:

• [LHP588 Phase 2 P. gingivalis trial](/clinical-trials/lhp588-phase2-p-gingivalis-nct06847321)
• [E2814 4R Tau Phase 2](/clinical-trials/e2814-4r-tauopathy-phase-2-nct05615614)
• [AL002 TREM2 Agonist](/clinical-trials/al002-trem2-agonist-alzheimers)
• [KI scale expansions]

References

Related Pages

• [Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease-trials)
• [Merck Pharmaceuticals](/companies/merck-msd)
• [Phase 2 Clinical Trials](/clinical-trials/phase-2-trials)
• [Amyloid-Targeting Therapies](/mechanisms/amyloid-cascade)
• [Neuroinflammation in Alzheimer's](/mechanisms/neuroinflammation)

Alzheimer's Disease Treatment Landscape

Current Standard of Care

The current treatment paradigm for AD includes:

• [Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)](/genes/ace)
• [NMDA receptor antagonist (memantine)](/entities/nmda-receptor)
• [Combination therapy (donepezil + memantine)](/genes/th)

• [Amyloid-targeting antibodies (lecanemab, donanemab)](/genes/ar)
• [Recently approved (2023-2024)](/proteins/app)
• [Significant controversy regarding benefit/risk](/genes/ar)

Unmet Medical Need

Despite recent approvals, significant unmet need remains:

• [Symptomatic treatments**: Modest efficacy, do not address disease](/treatments)progression
• Disease-modifying therapies: Associated with ARIA, limited to early disease
• Prevention: No approved therapies for pre-symptomatic stages
• Combination approaches: Not well explored in AD

Challenges in AD Drug Development

Historical Context

• 99% failure rate for disease-modifying therapies
• Over 200 failed clinical trials
• Multiple high-profile late-stage failures

Key Challenges

Merck's Neuroscience Pipeline

Historical Context

Merck has a long history in neuroscience drug development:

• Previous successes: Petolerant, Rebif, etc.
• Lecanemab development: Originally by Biogen, Merck involved in earlier work
• Current focus: Novel mechanisms beyond amyloid

MK-1167 Development

While the specific mechanism is undisclosed, several possibilities:

• Modulation of glutamate or GABA signaling
• Non-NMDA receptor approaches

• Microglial modulation
• Peripheral immune system effects

• Mitochondrial function
• Energy metabolism modulation

• AMPA receptor modulators
• Dendritic spine stabilization

Industry Trends

Merck represents a larger trend:

• Beyond amyloid: Focus on complementary mechanisms
• Academic partnerships: Leveraging university research
• Precision medicine: Biomarker-driven approaches

Clinical Trial Design Considerations

Phase 2 Trial Architecture

Dose-Finding Components

• Multiple dose cohorts
• Randomized, placebo-controlled
• Dose-escalation or parallel design

Patient Population Selection

• Mild to moderate disease: Most common for Phase 2
• Biomarker confirmation: Increasingly important
• Exclusion criteria: Manage comorbidities

Outcome Measures

Primary Endpoints

• Cognitive measures: ADAS-Cog, MMSE, CDR
• Clinical global: CIBIC+, CGI-C
• Functional: ADL, FAQ

Secondary Endpoints

• Biomarkers: CSF, imaging
• Brain volumes: MRI measures
• Quality of life: QoL-AD
• Biomarker targets: Target engagement

Statistical Considerations

• Sample size: 350 is moderate for Phase 2
• Duration: 2-year timeline suggests meaningful endpoints
• Power: Designed to detect moderate effects

Future of AD Therapeutics

Emerging Approaches

Novel Mechanisms in Development

• Anti-tau antibodies
• Small molecule inhibitors
• Tau aggregation inhibitors

• Mitochondrial protectors
• Antioxidants
• Neurotrophic factors

• Microglial modulators
• Peripheral immune approaches
• TREM2 targeting

• GLP-1 analogs
• Metabolic enhancers

Precision Medicine in AD

The field is moving toward:

• Biomarker-driven selection: Amyloid-positive, tau-positive
• Genetic subtypes: APOE, other genetic variants
• Endophenotypes: Different biological subtypes
• Combination therapies: Multi-target approaches

Regulatory Landscape

Recent Approvals

• Lecamab (Leqembi): Accelerated approval, full approval
• Donanemab (Kisunla): Conditional approval
• Aduhelm: Withdrawn from market

Implications for MK-1167

• Regulatory flexibility: More open to novel mechanisms
• Endpoint evolution: Accepting biomarker endpoints
• Conditional approval: Possible with limited efficacy

Strategic Considerations

Why Adjunctive Therapy?

The adjunctive approach makes sense because:

• Standard of care: Builds on existing treatments
• Regulatory path: Clear comparators
• Patient population: Larger pool than monotherapy
• Commercial potential: Multiple options for patients

Collaboration with Academic Centers

University of Kansas ADRC partnership suggests:

• Academic expertise: Clinical trial infrastructure
• Biomarker capabilities: Advanced diagnostics
• Patient access: Regional recruitment
• Scientific input: Mechanistic guidance

Timeline Analysis

• Start 2025: Expected recruitment timeline
• Completion 2027: 2-year treatment + follow-up
• Potential filing: 2028-2029 if successful

Summary

The MK-1167 trial represents:

• Novel mechanism: Merck's approach beyond amyloid
• Phase 2 design: Standard for mid-stage development
• Adjunctive approach: Building on existing therapies
• Academic collaboration: Leveraging university expertise
• Timeline: 2-year study with 350 participants

Pathway Diagram

The following diagram shows the key molecular relationships involving MK-1167 Phase 2 Alzheimer's Disease Trial discovered through SciDEX knowledge graph analysis: